Elite Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Elite Pharmaceuticals, Inc. (ELTP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.83 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-06-29
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2026 was $2.83M, a 14140.97% increase from fiscal 2025.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $19.84K.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $22.17K, a 29.64% decline from fiscal 2015.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $31.51K, a 69.09% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2026-03-31 | $2.83M 10-K · filed 2026-06-29 |
| 2025-03-31 | $19.84K 10-K · filed 2025-06-30 |
| 2016-03-31 | $22.17K 10-K · filed 2016-06-15 |
| 2015-03-31 | $31.51K 10-K · filed 2016-06-15 |
| 2014-03-31 | $101.96K 10-K · filed 2016-06-15 |